The latest update is out from AstraZeneca ( (GB:AZN) ).
AstraZeneca announced that its investigational drug eneboparatide met the primary endpoint in the Phase III CALYPSO trial, showing significant efficacy in normalizing serum calcium levels in adults with chronic hypoparathyroidism at 24 weeks. This result highlights eneboparatide’s potential as a new treatment option for this rare endocrine disorder, which affects over 200,000 people in the US and EU. The trial will continue to 52 weeks to further assess the drug’s risk-benefit profile, with full data expected to be shared with global health authorities and presented at medical meetings.
More about AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in areas such as Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. The company is headquartered in Cambridge, UK, and its medicines are available in over 125 countries. Alexion, a part of AstraZeneca, specializes in rare diseases and is dedicated to developing life-changing medicines for patients with significant unmet needs.
YTD Price Performance: 16.25%
Average Trading Volume: 2,817,366
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: £186B
For detailed information about AZN stock, go to TipRanks’ Stock Analysis page.